Clinical Trial Update: Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination therapy of temsirolimus and sorafenib in radioactive iodine-refractory thyroid cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Sorafenib (Sorafenib)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-08-15